Wyeth Research has signed a services agreement with microarray service firm Expression Analysis for contract pharmacogenomics testing services on Affymetrix GeneChips.
The 12 to 18 month contract will involve multiple clinical trials in various disease areas, according to Steve McPhail, President and CEO of Expression Analysis.
"This is a very significant agreement for us," McPhail told Pharmacogenomics Reporter. "Over the past two years, we have built up our infrastructure to facilitate the use of microarray technology in clinical trials, [and] this is the first pharmaceutical company that we have inked an agreement with to support multiple clinical trials.”
The companies said that all services provided under the agreement would be compliant with good laboratory practices for clinical trial studies, under 21 CFR Part 58. Expression Analysis, of Durham, NC, announced that its services were GLP compliant in late May. The company said that it is the first Affymetrix service provider to become GLP compliant.
EA will use Affymetrix' whole genome gene expresson chips, the U133 2.0 plus, in the work, McPhail said. Wyeth will send the clinical trial patient samples to EA's Durham, NC facility for testing, and EA will send back raw data, according to McPhail.
Expression Analysis, which began as a spin-out in September 2001 from Duke University's Affymetrix microarray core facility, garners over two-thirds of its business from pharmaceutical, biotech, and diagnostic companies, McPhail said. Over 30 percent of the company's business is in toxicogenomics and pharmacogenomics . "We really do see pharmacogenomics as a significant opportunity for us to increase our business over the next two to five years," McPhail said.